HK Stock Market Move | BOAN BIOTECH (06955) surged more than 4%, and the enrollment of all patients in the Chinese Phase III clinical trial of Navulimab monoclonal antibody is complete.

BOAN BIOTECH (06955) rose over 4%, as of the latest report, it rose by 3.46% to 10.48 Hong Kong dollars, with a turnover of 45.9821 million Hong Kong dollars. In terms of news, on October 30, BOAN BIOTECH announced that the company's independently developed BA1104 (Nivolumab Injection) has completed all patient enrollment in its phase III clinical trial in China. BA1104 is leading in development progress and is the first domestic biosimilar drug to conduct a phase III clinical trial for Opdivo in China. According to reports, BA1104 follows the research guidelines for biosimilar drugs and the phase III clinical trial conducted in China is a randomized, double-blind, multicenter trial aimed at comparing the efficacy, safety, and immunogenicity of BA1104 and Opdivo in combination with chemotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma. According to the "Guiding Principles for Biosimilar Similarity Assessment and Extrapolation of Indications", after completing the phase III clinical trial, BA1104 can apply for approval of all indications for which Opdivo has been approved in China. The results of the completed phase I clinical trial show that BA1104 is highly comparable to Opdivo in terms of pharmacokinetics, safety, and immunogenicity, meeting all study endpoints, and the relevant research results have been published in the international journal "BioDrugs".